Managed Care - January 2008 - (Page 9) GARDASIL—today, you can do more Quadrivalent efficacy against multiple HPV*-related diseases caused by Types 6, 11, 16, and 18: CERVICAL CANCER CERVICAL DYSPLASIA AND GENITAL WARTS *HPV=human papillomavirus. GARDASIL is a vaccine indicated in girls and women 9 to 26 years of age for the prevention of cervical cancer, precancerous or dysplastic lesions, and genital warts caused by HPV Types 6, 11, 16, and 18. A complete vaccination regimen of GARDASIL consists of a 3-dose schedule. See the Dosage and Administration section of the Prescribing Information. Select safety information GARDASIL is contraindicated in individuals who are hypersensitive to the active substances or to any of the excipients of the vaccine. GARDASIL does not substitute for routine cervical cancer screening, and women who receive GARDASIL should continue to undergo screening per standard of care. Vaccination with GARDASIL may not result in protection in all vaccine recipients. GARDASIL is not intended to be used for treatment of active genital warts; cervical cancer; cervical intraepithelial neoplasia, vulvar intraepithelial neoplasia, or vaginal intraepithelial neoplasia. The vaccine-related adverse experiences that were observed among recipients of GARDASIL at a frequency of at least 1.0% and greater than placebo were pain, swelling, erythema, fever, nausea, pruritus, and dizziness. Please read Brief Summary of Prescribing Information on adjacent page. Your recommendation matters—vaccinate today GARDASIL is a registered trademark of Merck & Co., Inc. Copyright © 2008 Merck & Co., Inc. All rights reserved. 20752942(1)(305)-GRD http://www.merckvaccines.com
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.